5-HT2A Inverse Agonist Derivatives With Reduced Cardiovascular Effects

The patent applies parameter changes by modifying the chemical structure of serotonin receptor ligands to achieve selective inverse agonism at 5-HT2A and 5-HT2C receptors. The compounds of Formula (I) and (II) represent specific molecular parameter modifications that differentiate them from existing agents, enabling targeted receptor interaction that provides symptom relief while minimizing side effects on the cardiovascular system and motor function.

The patent applies local quality by designing compounds with specific molecular characteristics that confer selective affinity for 5-HT2A and 5-HT2C receptors while reducing interaction with cardiovascular receptors. The structural features in Formula (I) and (II), including specific substituent patterns and heterocyclic moieties, create localized molecular properties that enable selective receptor binding, thereby maintaining psychiatric efficacy while reducing cardiovascular adverse effects compared to pimavanserin.

The patent applies the intermediary principle by developing compounds that act as selective serotonin receptor inverse agonists to mediate therapeutic effects. The compounds of Formula (I) and (II) serve as intermediary agents that specifically target 5-HT2A and 5-HT2C receptors, providing a mechanism for both symptomatic relief and potential disease modification through selective receptor modulation, unlike existing agents that lack this specificity.